Itation at 488 nm and emission at 585 nm. MAGPIX method. Phycoerythrin with excitation at 488 nm and emission at 585 nm.Analytica 2021, 2, FOR PEER Review Analytica 2021,6The two assays enabled us to profile levels of ARG1 and Ac-dA Phosphoramidite Cancer miR-122 within a DILI patient. The two Table enabled us to profile levels of ARG1 higher levels within a DILI patient. As As reported in assays S4, the patient with DILI presentedand miR-122of each ARG1 and reported in Table S4, the patient with DILI presented high levels of each ARG1 and miR-122, miR-122, even though, and as anticipated, the no DILI patient did not show considerable levels of even though, and as miR-122. the no DILI patient didn’t show important levels of either ARG1 either ARG1 or anticipated,ARG1 and miR-122 levels have been quantified utilizing the two calibraor miR-122. ARG1 with all the data reported in Tables S2 and S3, respectively. Levels of tion curves generatedand miR-122 levels were quantified working with the two calibration curves generated together with the data reported in Tables S2 and S3, respectively. Levels Figure two. ARG1 and miR-122 have been extrapolated and reported in Table S4 and shown inof ARG1 and miR-122 were extrapolated and reported in Table S4 and shown in Figure 2.Figure two. ARG1 and miR-122 calibration curves with interpolated ARG1 and miR-122 from DILI Figure 2. ARG1 and miR-122 calibration curves with interpolated ARG1 and miR-122 from DILI samples. Error bars ( s.d.) determined by triplicate measurements. The error bars are smaller than the samples. Error bars ( s.d.) based on triplicate measurements. The error bars are smaller than the size of some data points. n = three. size of some information points. n = three.three.two. AdipoRon Protocol seqCOMBO Assay–Analysis of ARG1 and miR-122 Simultaneously 3.two. SeqCOMBO Assay–Analysis of ARG1 and miR-122 simultaneously The two person assays described in Figure 1a,b have been combined delivering the The two to profile assays described the levels of ARG1 combined delivering the seqCOMBOindividual at the same time in Figure 1a,b had been and miR-122 in the serum seqCOMBO a DILI patient. As shown in Figure 3,of ARG1 and miR-122 in the serum of nine sample of to profile at the identical time the levels the seqCOMBO workflow consists sample of asteps. patient. As shown in Figure three, the seqCOMBO workflow consists of nine main DILI principal actions.seqCOMBO enables profiling levels of ARG1 and miR-122 within the DILI patient. Because the The seqCOMBO and shown in Figure two, the patient with DILI within the DILI patient. reported in Table S4enables profiling levels of ARG1 and miR-122 presented high levels As reported in Table S4 and shown in Figure 2,expected, the noDILI presented higher levels of each ARG1 and miR-122, although, and as the patient with DILI control did not show ofsignificant levels of ARG1 or miR-122. No signal loss was no DILI controlboth protein and both ARG1 and miR-122, whilst, and as anticipated, the observed when didn’t show significantwere analysed via seqCOMBO in the similar time. observed when each protein miRNA levels of ARG1 or miR-122. No signal loss was and miRNA were analysed via seqCOMBO at the same time. seqCOMBO is utilised, an interTo examine how the signal varies when singleplex or CVTo comparegenerated, comparing the MFI signals obtained for person analysis vs. study was how the signal varies when singleplex or seqCOMBO is used, an interCV study was generated,in Table 1. TheseMFI signals obtainedthe MILIPLEX xMAP kit can seqCOMBO, as shown comparing the results indicate that for person analysis vs. seqCOMBO, with the DCL met.